C. difficile

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
CP Wire
Summit Therapeutics
C. difficile
microbiome ridinilazole
Flag link:
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
Endpoints
JNJ
Actelion
antibiotics
C. difficile
cadazolid
Flag link:
Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report
Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report
Fierce Pharma
Pfizer
Valneva
Sanofi
C. difficile
vaccines
PF-06425090
Flag link:
Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure
Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure
Endpoints
Sanofi
C. difficile
vaccines
clinical trials
Flag link:
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Endpoints
Takeda
Finch Therapeutics
Crestovo
C. difficile
microbiome
CP101
Flag link:
Pfizer says mid-stage trial for C. difficile vaccine had positive results
Pfizer says mid-stage trial for C. difficile vaccine had positive results
Marketwatch
Pfizer
clinical trials
C. difficile
vaccines
Flag link:
Facing Cubicin generic threat, Merck's antibiotics biz gets a nudge with new C. diff-fighter Zinplava
Facing Cubicin generic threat, Merck's antibiotics biz gets a nudge with new C. diff-fighter Zinplava
Fierce Pharma
Merck
Cubicin
generics
C. difficile
Zinplava
antibiotics
Flag link:
Merck Has An Upcoming PDUFA Date For Bezlotoxumab
Merck Has An Upcoming PDUFA Date For Bezlotoxumab
Yahoo/Benzinga
Merck
bezlotoxumab
C. difficile
Flag link:
U.S. regulatory panel backs approval for Merck C. difficile drug
U.S. regulatory panel backs approval for Merck C. difficile drug
Yahoo/Reuters
FDA
Merck
C. difficile
advisory panels
bezlotoxumab
Flag link:
FDA staff review questions efficacy of Merck's C. difficile drug
FDA staff review questions efficacy of Merck's C. difficile drug
Yahoo/Reuters
FDA
Merck
C. difficile
bezlotoxumab
Flag link:
Merck antibody reduces risk of C. difficile recurrence - study
Merck antibody reduces risk of C. difficile recurrence - study
Yahoo/Reuters
Merck
C. difficile
antibodies
Flag link:
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
Yahoo/PR Newswire
Synthetic Biologics
C. difficile
P3A
P4A
Flag link:
Sanofi SA announces favorable Phase II study results for investigational Clostridium difficile Vaccine
Sanofi SA announces favorable Phase II study results for investigational Clostridium difficile Vaccine
Reuters
C. difficile
Sanofi
vaccines
Flag link:
Nanosphere receives FDA clearance for C. difficile test
Nanosphere receives FDA clearance for C. difficile test
Yahoo/Fly on the Wall
Nanosphere
FDA
C. difficile
devices
Flag link:
FDA Approves Optimer's DIFICID (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)
FDA Approves Optimer's DIFICID (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)
Yahoo/PR NewsWire
Clostridium Difficile
C. difficile
Optimer
Dificid
Flag link:
Meridian Bioscience wins Canadian OK for C. difficile test
Meridian Bioscience wins Canadian OK for C. difficile test
Meridian Bioscience
Canada
diaganostics
C. difficile
Flag link:
Optimer Pharma rises on fidaxomicin study data
Optimer Pharma rises on fidaxomicin study data
Yahoo/AP
Optimer
C. difficile
fidaxomicin
Flag link: